Delivery Order SPE2DB22D2005-SPE2DB23FJNB4

Award Date 4/17/23
Potential Completion Date 4/18/23
Potential Value $3.5K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $1,204.12, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract covers the delivery of Lidocaine 5% patches, a pharmaceutical product, with an ultimate completion date of October 19, 2023. The contract was awarded as a Delivery Order under an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which Cencora, Inc. holds with the DLA Troop Support Medical. This IDC serves...
This federal contract award, valued at $7,182.17, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Lidocaine 5% Patch 30s, a pharmaceutical product, with a completion date of January 19, 2024. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running...
This federal contract award, valued at $13,179.76, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Lidocaine 5% Patch 30s, a pharmaceutical product, to support military and federal healthcare programs. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. holds with the DLA Troop Support Medical. This...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award is for the delivery of Lidocaine 5% Patch 30s, a pharmaceutical product, with a ceiling value of $1,013.09 and a period of performance through January 19, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00...
This federal contract award, valued at $1,194.07, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Lidocaine 5% Patches, with a period of performance through December 1, 2023. The award is part of a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary...
This federal contract award, valued at $10,754.39, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Lidocaine 5% Patch 30s, a pharmaceutical product, with a period of performance through December 20, 2023. The award is structured as a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at up to...
This federal contract award, valued at $63,642.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Lidocaine 5% patches to support the DLA Troop Support Medical program, which provides essential pharmaceutical and medical supplies to military healthcare facilities worldwide. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA, valued...
This federal contract award, valued at $14,491.88, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Lidocaine 5% Patch 30s, a pharmaceutical product, to support military treatment facilities and veterans' healthcare programs. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $4,622.04, is for the delivery of Lidocaine 5% patches. The contract type is a Delivery Order with a Firm Fixed Price pricing structure. The ultimate completion date is January 26, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical,...
This federal contract award, valued at $76,411.70, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract provides for the delivery of 4558424114 - Lidocaine 5% Patch 30s, a pharmaceutical product, to support military healthcare programs. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to...
  • SPE2DB22D2005
    Indefinite Delivery Contract
  • SPE2DB22D2005-SPE2DB23FJNB4
    Delivery Order

This federal contract award, valued at $3,501.95, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Lidocaine 5% Patch 30s, a pharmaceutical product, and has an ultimate completion date of April 18, 2023.

The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC enables the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating full and open competition.

Generated 5/9/25, 10:16 AM